Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
|Cantor Global Healthcare Conference Presentation Information:|
|Format||Fireside chat discussion and 1-on-1 meetings|
|Time:||Discussion available on demand beginning
|To Listen||To listen to the discussion, click here. A replay will be archived for 30 days at this link (or go to www.sol-gel.com to access within the Investors/Events and Presentations section).|
Sol-Gel is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.
The Company’s pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment of palmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment of plaque psoriasis and other dermatologic indications.
For additional information, please visit www.sol-gel.com.
Investor relations, LifeSci Advisors
Chief Financial Officer
Source: Sol-Gel Technologies Ltd.